SHINE Technologies has raised $240M to expand its nuclear medicine operations, including large-scale production of Lutetium-177 used in targeted cancer therapies, following its recent acquisition of Lantheus’ SPECT business...

Published by Nucleation Capital in Advanced Nuclear, Company Milestone, Fusion, Medical Isotopes, Neutron services, NEWS, Nuclear financing, Nuclear R&D, Portfolio Venture, Private companies, Venture capital support for nuclear